Anti-SARS-CoV-2 Revaccination Success in Kidney Transplant Recipients With No Initial Humoral Response Is Linked to Primary Vaccine Type
BackgroundWhile anti-SARS-CoV-2 vaccination success in kidney transplant recipients (KTR) after two doses and 1273-mRNA was associated with higher seroconversion rates compared to BNT162b2-mRNA in our “DIA-Vacc Study” (NCT04799808), it remains unclear whether this may also be the case in non-respond...
Main Authors: | Julian Stumpf, Jörg Schwöbel, Claudia Karger, Holger Schirutschke, René Mauer, Anna Klimova, Torsten Tonn, Christian Hugo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.910987/full |
Similar Items
-
Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
by: Daniele Focosi, et al.
Published: (2022-11-01) -
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
by: Chiranjib Chakraborty, et al.
Published: (2021-07-01) -
Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees
by: Gabriele Anichini, et al.
Published: (2022-05-01) -
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
by: Miriam Echaide, et al.
Published: (2023-03-01) -
Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)